Pulmonary

IFITM3 drives SCLC immunotherapy response
The protein serves as a key indicator of how a patient with small cell lung cancer will react to current treatments.
September 10, 2025
Getty Images 2187784917
Peeling back the layers of pulmonary fibrosis
Exploration of the disease in early stages sheds light on initial chain reaction and inevitable feedback loop.
September 9, 2025
Claudia Loebel, MD, PhD, preparing samples in the lab.
Fresh understanding of African Americans’ sensitivity to lung cancer
Data shed light on some of the genetic sources behind the predisposition.
September 4, 2025
Getty Images 1392802429
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2025 to 2034.
April 10, 2025
Pulmonary drug market forecast
ALA launches new pulmonary fibrosis support program
In connection with Pulmonary Fibrosis Awareness Month this September, the free resource can help people living with or caring for those with PF.
September 3, 2025
Getty Images 2167107009
Solutions to make RNA therapies safer
Modifications to lipid nanoparticles help block lung inflammation and reduce damage.
August 29, 2025
Getty Images 2151198847
Cystic fibrosis patients at risk of persistent lung infection
Despite new drugs called modulators, research shows bacterial infections remain hard to clear.
August 28, 2025
Air trapping (colored pink) in lungs of a cystic fibrosis patient before CFTR modulator treatment.
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2025 to 2034.
April 10, 2025
Pulmonary drug market forecast
Computerized decision support benefits children on ventilators for lung failure
Patients experienced less time spent on mechanical support and improved recovery.
August 22, 2025
Getty Images 2153665059
Brinsupri becomes first FDA-approved therapy for NCFB
The important decision was made following positive results from the ASPEN and WILLOW trials.
August 21, 2025
Getty Images 2184939212
Overlooked protein could alter outcome of lung disease
Epac1 has potential as a new drug target for idiopathic pulmonary fibrosis.
August 8, 2025
AM-001 blocks a key protein (Epac1), which helps protect another protein (FoxO3a) from being broken down. It also shuts down several harmful signals that drive lung scarring in idiopathic pulmonary fibrosis, helping to reduce lung damage.
Sponsored
Pulmonary drug market forecast
Ascend Media
Review analysis, trends and predictions for pulmonary drug delivery systems, 2025 to 2034.
April 10, 2025
Pulmonary drug market forecast
How lymphatic vessels help heal by switching gears
The protein PAR1 triggers a process that clears inflammation and repairs lung damage.
August 7, 2025
Lymphatic vessels (green) are wrapped around blood vessels (red) in a mouse lung. The PAR1 protein triggers lymphatic vessels to be permeable, so they can absorb more fluid and immune cells for healing—a response distinct from blood vessels, where similar changes result in leakage and disease.
CHEST publishes new guideline on NSCLC management
The evidence-based recommendations will help establish standard of care treatment for patients with early-stage disease.
August 6, 2025
Getty Images 2204506575
Eliminating race from lung function assessments
Physicians, researchers push to update AMA guidelines to improve pulmonary impairment testing process.
August 4, 2025
Getty Images 1420686338
Page 1 of 21
Next Page
Most Popular
A diet high in saturated fat linked to increased lung inflammation
Brinsupri becomes first FDA-approved therapy for NCFB
The best and worst states for lung health, COPD
Father’s exposure to passive smoking could pass lung problems along to children
Machine learning model enhances asthma drug prediction accuracy
Solutions to make RNA therapies safer